Create a supply chain adaptable to disruption and able to contribute to strong environmental and social performance.
- Global Public Health
- Inclusion, Diversity & Equity
Working to strengthen healthcare systems across the world by developing and deploying market-appropriate solutions
BD Global Public Health works to align activities, priorities and development efforts around the world's leading public health needs. We drive access to existing BD solutions and develop and deploy innovations to address priority health needs in areas aligned with the Sustainable Development Goals (SDGs).
To achieve positive societal outcomes, we utilize various methods including innovative commercial business models, public-private partnerships, market development activities and global advocacy. Established in 2004, BD Global Public Health champions private sector engagement with international agencies, nongovernmental organizations and governments on global, regional and local levels with a goal to enhance access to health for all people.
Collaborating to help curb the spread of resistant infections
Antimicrobials—drugs that kill infectious bacteria, viruses, parasites and fungi—are a mainstay of modern medicine. However, limited development of new medicines and decades of outmoded use have driven increases in the number of microbes resistant to these lifesaving drugs.
Our ongoing efforts align with best practices that control antimicrobial resistance (AMR) and include a broad portfolio of AMR solutions that support the following areas:
- Infection prevention and control. BD capabilities help reduce the incidence of healthcare-associated infections (HAIs) and the spread of antimicrobial-resistant organisms.
- Diagnostic testing. BD capabilities enable clinicians to accurately identify infections, appropriately tailor treatment and avoid unnecessary antibiotic use.
- Surveillance and reporting. BD efforts help identify patients at greatest risk of acquiring resistant infections, monitor population-based trends and provide early warning for outbreaks.
Collectively, these capabilities enhance our customers' ability to contain AMR and achieve effective antimicrobial stewardship. Our recently formed, cross-company AMR team, working with the Office of the UN Secretary-General's Special Envoy for Health in Agenda 2030 and for Malaria, the UK Mission to the United Nations, the Joint United Nations Programme on HIV/AIDS (UNAIDS), United Nations Unies and the Review on Antimicrobial Resistance, has helped organize forums at events such as the United Nations General Assembly meeting in New York and the World Economic Forum Annual Meeting in Davos, Switzerland. Featured speakers have included Prof. Dame Sally Claire Davies, Chief Medical Officer for England; Lord Jim O'Neill, Chair of the AMR Review and U.K. Commercial Secretary to the Treasury; and Dr. Thomas Frieden, Director of the U.S. Centers for Disease Control and Prevention. At the UN General Assembly meeting, Renuka Gadde from BD Global Public Health stated that "AMR has no single solution, and the challenges cannot be solved without multiple players working collectively on a common AMR agenda."
BD solutions to combat antimicrobial resistance
Global stakeholders join forces in the fight against antimicrobial resistance
Addressing healthcare challenges through cross-sector collaborations with key local, regional and global organizations
Bringing the private sector point of view to leading funders, international agencies and the U.S. government
Health systems strengthening
Deploying BD capabilities and technology solutions to help address the world's most pressing health needs
Channeling products, resources and collaborative efforts to address fundamental health issues
A holistic approach is needed to combat complex infectious diseases such as TB and HIV & AIDS.
BD Global Public Health applies the company's technologies, resources and expertise across the continuum of care required to address these problems—from preventing disease transmission, to diagnosing infection, to monitoring treatment, to providing essential educational training for healthcare workers.
Addressing unmet societal needs with profitable business models
As a company, BD embraces the strategy of shared value.
BD Global Public Health utilizes various methods to achieve positive societal outcomes including public-private partnerships, market development and public policy. BD also works with external funders and scientific collaborators to incubate global health technologies that address unmet needs in emerging nations.
BD has made the following notable advancements:
- The BD Uniject™ auto-disable pre-fillable injection system for family planning
- Partnership for Sayana® Press, an all-in-one injectable contraceptive system that utilizes the BD Uniject auto-disable pre-fillable injection system
- Partnership with CHAI to expand access to CD4 testing
- BD and USAID collaboration to support Indonesia's National Tuberculosis Program (NTP)
Read more about the Shared Value Initiative
At BD, we view sustainability as a portfolio of complementary initiatives and actions that help us achieve our purpose of advancing the world of health. We see the modern social and environmental challenges our world faces as opportunities to make a difference while strengthening our company.
Our 2030+ sustainability strategy, which focuses on five impact areas, addresses a range of challenges in our industry while helping to make a difference on relevant issues that affect society and the planet. Our strategy will ensure we remain focused on shared value creation—meaning how we address unmet societal needs through business models and initiatives that also contribute to the commercial success of BD.
UN Sustainable Development Goals
At BD, we actively evaluate how we can mobilize and contribute to the achievement of the UN Sustainable Development Goals (SDGs), through our product and service offerings, as well as collaborative efforts across various sectors-most prominently around SDG3, for good health and well-being. The case study below demonstrates our efforts to advance the SDGs.
Minimize our contribution to global emissions and utilize our capabilities to address unmet health needs for climate-vulnerable populations.
Reduce the environmental impact of our portfolio and address the sustainability needs of our customers.
Maintain a healthy and thriving workforce that cultivates our culture of inclusion, safety, well-being and contributes to community health.
Invite trust across stakeholder groups through transparent performance reporting on environmental, social and governance (ESG) issues relevant to our business.
We are the Makers of Possible
Inclusion, Diversity and Equity at BD
We are the people who give possibilities purpose, and our Purpose serves as a foundation for who we are as a company. Our inclusion, diversity and equity (ID&E) goals fulfill our Purpose, empower our workforce, drive innovation, and create a more inclusive environment. And we’re always working to reinvent the future of healthcare, to discover possibilities that once seemed unimaginable. This has enabled us to establish ourselves as the backbone of healthcare on which many health systems depend.
We are committed to maintaining a healthy and thriving workforce that cultivates our culture of inclusion, safety and well-being. Our inclusion, diversity and equity efforts facilitate an environment where our associates are included in key decisions and play a crucial role in developing the transformative solutions that impact lives around the globe. Our progress in ID&E drives our culture, differentiates us as a company, and is vital to our ability to achieve dynamic leadership in the MedTech industry.
Our most recently filed U.S. Federal Employment Information Report (EEO-1) is available for download. The data in the consolidated EEO-1 report is based on BD’s population in the U.S. in December 2021 and reflects BD’s U.S. workforce as of that time. The EEO-1 report requires that we categorize employees into ten broad EEO-1 Component 1 Data Collection Job Categories. These categories do not necessarily match the job levels in which BD organizes its workforce and evaluates its diversity and inclusion data. Thus, meaningful comparisons between EEO-1 Report data and other descriptions of BD’s diversity statistics and disclosures may not be possible.
Cautionary statement regarding forward-looking statements
This report contains certain forward-looking statements within the meaning of the federal securities laws regarding the BD ID&E strategy, goals, commitments and objectives. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed, projected, anticipated or implied in such statements. All statements, other than statements of historical facts, may be forward-looking statements. Some forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “may,” “anticipate,” estimate,” “target,” and other words of similar meaning. Readers should not place undue reliance on forward-looking statements. Forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events, developments and operating performance, and speak only as of their dates.
Statements regarding the company’s goals, commitments and objectives may include statistics or metrics that are based on estimates and assumptions. Such goals, commitments and objectives are not intended to be promises or guarantees, and actual results may differ, possibly materially. It is not possible to predict or identify all of these risks and uncertainties that could cause actual results to differ, many of which are beyond the company’s control, including, without limitation, challenges relating to economic, competitive, governmental and technological factors affecting the company’s operations, markets and products, and other factors listed in the BD 2022 Annual Report on Form 10-K and other filings with the Securities and Exchange Commission (SEC). BD expressly disclaims any undertaking to update or revise any forward-looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.
The inclusion of information in this report should not be construed as a characterization regarding the materiality or financial impact of that information. For additional information regarding BD, please see our 2022 Annual Report on Form 10-K and other filings with the SEC.
This report contains links to external websites or references to third parties. Such links or websites are not endorsements of any products or services on such sites, and no information in such site has been endorsed or approved by BD or incorporated into this report.
To find out more about ID&E and sustainability at BD or to provide feedback on our reporting, please contact BD_Sustainability_Office@bd.com.
BD, the BD Logo and Advancing the world of health are trademarks of Becton, Dickinson and Company. ©2022 BD. All rights reserved.
At BD, we're passionate about advancing the world of health—and that passion extends through our approach to social investing. Our company values guide us to "do what's right," "take personal responsibility," and to "respect, collaborate with, challenge and care about each other." And those commitments apply not just to the way we do business—but also to the ways we give back to the local and global community.
We leverage our expertise to collaborate with leading nonprofit organizations to address unmet healthcare needs. We focus on improving healthcare access and strengthening the capacity of health systems to care for all patients, especially the most vulnerable.
BD partners with leading nonprofit organizations to address unmet healthcare needs.
BD encourages its employees to get involved and give back to their local communities.
Learn more about BD's approach to disaster response and product donation.